Show simple item record

dc.contributor.authorScarffe, J Howard
dc.contributor.authorChang, James
dc.date.accessioned2010-09-10T15:33:53Z
dc.date.available2010-09-10T15:33:53Z
dc.date.issued1989
dc.identifier.citationFailure of lithium to reduce period of neutropenia during induction therapy of acute myeloid leukemia., 7 (1):69-75 Hematol Oncolen
dc.identifier.issn0278-0232
dc.identifier.pmid2491829
dc.identifier.doi10.1002/hon.2900070108
dc.identifier.urihttp://hdl.handle.net/10541/111034
dc.description.abstractFifty-four patients treated with daunorubicin, cytosine arabinoside and thioquanine for acute myeloid leukemia were randomly assigned to receive oral lithium carbonate 1200 mg daily or no lithium. The duration of neutropenia (less than 0.5 x 10(9)/L) was similar between controls (median 22.5 days) and patients treated with lithium (median 24 days). The number of remissions, relapse-free survival and survival were similar for the lithium treated and control groups of patients. There was no apparent clinical efficacy in the use of lithium to reduce the period of neutropenia in patients undergoing remission induction therapy for acute myeloid leukemia.
dc.language.isoenen
dc.subjectAcute Myeloid Leukaemiaen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshAgranulocytosis
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.subject.meshDrug Evaluation
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshLeukemia, Myeloid, Acute
dc.subject.meshLithium
dc.subject.meshLithium Carbonate
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshNeutropenia
dc.subject.meshRandom Allocation
dc.subject.meshRemission Induction
dc.titleFailure of lithium to reduce period of neutropenia during induction therapy of acute myeloid leukemia.en
dc.typeArticleen
dc.identifier.eissn1099-1069
dc.contributor.departmentCRC Department of Medical Oncology, Christie Hospital, Manchester, U.K.en
dc.identifier.journalHematological Oncologyen
html.description.abstractFifty-four patients treated with daunorubicin, cytosine arabinoside and thioquanine for acute myeloid leukemia were randomly assigned to receive oral lithium carbonate 1200 mg daily or no lithium. The duration of neutropenia (less than 0.5 x 10(9)/L) was similar between controls (median 22.5 days) and patients treated with lithium (median 24 days). The number of remissions, relapse-free survival and survival were similar for the lithium treated and control groups of patients. There was no apparent clinical efficacy in the use of lithium to reduce the period of neutropenia in patients undergoing remission induction therapy for acute myeloid leukemia.


This item appears in the following Collection(s)

Show simple item record